US20220370717A1 - Syringe support and autoinjector - Google Patents
Syringe support and autoinjector Download PDFInfo
- Publication number
- US20220370717A1 US20220370717A1 US17/738,644 US202217738644A US2022370717A1 US 20220370717 A1 US20220370717 A1 US 20220370717A1 US 202217738644 A US202217738644 A US 202217738644A US 2022370717 A1 US2022370717 A1 US 2022370717A1
- Authority
- US
- United States
- Prior art keywords
- syringe
- housing
- injector
- auto
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940090047 auto-injector Drugs 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 claims description 30
- 239000004033 plastic Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 6
- 108010011459 Exenatide Proteins 0.000 description 6
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000012858 resilient material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 3
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229960001093 lixisenatide Drugs 0.000 description 3
- 108010004367 lixisenatide Proteins 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- -1 naked and cDNA) Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108091060283 mipomersen Proteins 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MSFZPBXAGPYVFD-NFBCFJMWSA-N (2r)-2-amino-3-[1-[3-[2-[2-[2-[4-[[(5s)-5,6-diamino-6-oxohexyl]amino]butylamino]-2-oxoethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound NC(=O)[C@@H](N)CCCCNCCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O MSFZPBXAGPYVFD-NFBCFJMWSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 241000270431 Heloderma suspectum Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229940014641 bydureon Drugs 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- TZRFSLHOCZEXCC-HIVFKXHNSA-N chembl2219536 Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 229950010300 denagliptin Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940098262 kynamro Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960004778 mipomersen Drugs 0.000 description 1
- OSGPYAHSKOGBFY-KMHHXCEHSA-A mipomersen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O OSGPYAHSKOGBFY-KMHHXCEHSA-A 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31571—Means preventing accidental administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
Definitions
- the disclosure relates to a syringe support and to an autoinjector.
- Administering an injection is a process that presents a number of mental and physical risks and challenges for users and healthcare professionals.
- Injection devices typically fall into two categories—manual devices and autoinjectors.
- manual force is required to drive a medicament through a needle. This is typically done by a plunger that has to be continuously pressed during the injection.
- a plunger that has to be continuously pressed during the injection.
- There are numerous disadvantages associated with this approach For example, if the plunger is released prematurely, the injection will stop and may not deliver an intended dose. Furthermore, the force required to push the plunger may be too high (e.g., if the user is elderly or a child). Additionally, aligning the injection device, administering the injection, and keeping the injection device still during the injection may require dexterity which some patients may not have.
- Autoinjector devices may be single-use or reusable devices and aim to make self-injection easier for patients.
- a conventional autoinjector may completely or partially replace activities involved in parenteral drug delivery from a manual device. Typically, such activities include removal of a protective syringe cap, insertion of the needle, providing the force for administering the injection and possibly removal and shielding of the used needle.
- One aspect of the present disclosure relates to a syringe support for supporting an axial position of a syringe relative to a housing of an autoinjector, wherein the syringe support comprises a projecting portion which projects from the syringe support into a distal direction and a flexible portion which axially adjoins the projecting portion and which is adapted to axially bias the syringe in the distal direction within the housing.
- the syringe support provides a secure arrangement of the syringe within the housing.
- the syringe is arranged within the housing less prone to failures and damages and allows tolerance compensation.
- the syringe support further ensures that the syringe is biased forward against forward stop and thereby ensures that the needle is always inserted to full insertion depth. In particular, the syringe does not move backward under force of piercing skin.
- the syringe support allows that syringes with different lengths due to manufacturing tolerances may be arranged within the same housing.
- the flexible portion is adapted to accommodate to syringes having different lengths.
- the flexible portion provides a secure arrangement by compensating different syringe lengths.
- the flexible portion is adapted to compensate variations in length of the syringe of maximum 5%, in particular 3%.
- the syringe support accommodates +/ ⁇ 1.5 mm syringe length for a syringe of 50 mm in length.
- the flexible portion On final assembly of the syringe into a housing of an autoinjector, after the syringe has been inserted and moved to its final assembling position inside the housing, the flexible portion, also called compliant backstop, deflects axially and thus provides an axial force on the syringe to bias it forward and so prevents its axial movement during storage, transportation, drop and use.
- the flexible portion is sized to accommodate the tolerances of both the syringe and the autoinjector, in particular the housing, whilst limiting the movement of the syringe during drop to prevent accidental de-booting of the syringe.
- the stiffness of the flexible portion is tailored to provide a minimum force required to restrain the syringe during storage, transportation, drop, and use so as to not unduly stress the syringe flange and for example risk glass fracture.
- the flexible portion is designed in the form of a web, in the form of a flexure beam or in the form of a spring arm.
- the flexible portion is of meander-shaped, accordion-shaped, labyrinth-shaped, U-shaped, V-shaped, W-shaped or S-shaped design.
- the flexible portion is of an accordion-shaped or labyrinth-shaped design to be maintained in a relaxed position and to form a stop for the syringe for compensating different syringe lengths.
- the flexible portion may be stressed during assembling of the syringe due to different lengths of the syringes to avoid or at least minimize risk of damages.
- the syringe is carried and holds by a syringe carrier at its distal end wherein the proximal end, namely the flange, of the syringe projects the proximal end of the syringe carrier so that the flexible portion, engaging the flange, deflects and further stresses axially rearwards so that the length of the syringe can be compensated.
- the flexible portion may be formed from resilient material.
- the flexible portion is designed to provide a reasonable compressive strength as well as a bending strength.
- the flexible portion may be formed from a corresponding resilient material, e.g. plastic, and/or with a corresponding structural design, e.g. horizontal and vertical webs and ribs.
- the projecting portion is stronger than the flexible portion, e.g. the plastic of the projecting portion is stronger than the plastic of the flexible portion.
- the resilient flexible portion could be in the form of a multiply bent arc of resilient material, wherein at least one end of the multiply bent arc is attached to the syringe support and an outer free end of the multiply bent arc is in juxtaposition with the flange of the syringe.
- the flexible portion axially extends in the distal direction.
- the flexible portion is located distally on the syringe support. Thereby, the distal flexible portion retains the syringe in position.
- the distal end of the distal flexible portion is a free end.
- the opposite proximal end of the distal flexible portion adjoins the projecting portion.
- more than one flexible portion may be arranged around the circumference of the syringe flange, thus the syringe is reliably held in position.
- the flexible portion is integrally formed with the projecting portion so that the flexible portion deflects axially rearwards against the projecting portion when the syringe is assembled or moves rearwards.
- the flexible portion may be integrally moulded with the syringe support for ease of manufacture, e.g. may be produced in an injection moulding die by injection moulding from plastic.
- the syringe support may comprise a number of projecting portions with adjoined flexible portions that interact with the flange of the syringe for providing length compensation or a damping and a restricting of an axial movement of smaller syringes rearwards when the syringe is assembled and in place within the housing.
- the flexible portions may be arranged around the circumference of the syringe flange, thus the syringe is reliably held in position.
- At least two flexible portions are arranged distally on the syringe support.
- the at least two flexible portions are arranged opposed to each other. More than two flexible portions may be provided and may be symmetrically arranged on the syringe support.
- the flexible portions are adapted to provide a secure axial support and positioning of the syringe relative to the housing in the rearward direction. Thus, a risk of breakage is reduced.
- an autoinjector comprises a syringe support as described above and a housing, wherein the housing comprises such a syringe support.
- the flexible portion and the flange of the syringe contact one another and are pressed onto one another so that the syringe is securely positioned.
- the flexible portion is distally attached to the projecting portion.
- the flexible portion is biased in the distal direction.
- the syringe support comprises at least two rigid projecting portions, e.g. rigid arms, wherein each rigid arm comprises one flexible portion.
- the two rigid arms are formed as inner arms which inwardly extend from a proximal outer housing part, e.g. a proximal end, into the housing.
- the housing comprises a front part and a rear part wherein the flexible portion is arranged on the rear part.
- the rear part comprises a proximal end from which the rigid arms are inwardly extended.
- the flexible portion is arranged on a distal end of the rigid arms.
- the housing comprises a proximal end which is larger than a proximal aperture of the housing.
- the proximal end of the rear part rests on the edge of the proximal aperture of the front part to proximally close the housing.
- FIG. 1 is a schematic perspective partial section of an exemplary embodiment of an autoinjector
- FIG. 2 is a schematic perspective view of an exemplary embodiment of a housing part comprising a syringe support from an inner end,
- FIG. 3 is a schematic perspective view of an exemplary embodiment of a housing part comprising a syringe support from a proximal end,
- FIG. 4 is a schematic perspective view of an exemplary embodiment of a separate single syringe support and a separate single rear part
- FIG. 5 is a schematic longitudinal section view of an exemplary embodiment of a housing part having a syringe support
- FIG. 6 is a schematic side view of a housing part having a syringe support
- FIG. 7A to 7C is a schematic view of different exemplary embodiments of a flexible portion of a syringe support
- FIG. 8 is a schematic side view of an exemplary embodiment of a housing part having a syringe support
- FIG. 9 is an explosion view of a rear part and a front part of a housing and
- FIG. 10 is a schematic perspective view of an exemplary embodiment of a syringe support and a syringe in an assembled state.
- FIG. 1 is a schematic perspective partial section of an exemplary embodiment of an autoinjector 1 in a state after assembly.
- the autoinjector 1 comprises a housing 2 including a sleeve-shaped front part 2 . 1 and a rear part 2 . 2 .
- the housing 2 may be formed as a one-piece housing (not shown).
- the housing 2 is adapted to hold a syringe 3 , e.g. a glass syringe.
- the syringe 3 may be a pre-filled syringe containing a liquid medicament M and have a needle 4 arranged on a distal end.
- the syringe 3 may be a cartridge which includes the medicament M and engages a removable needle (e.g., by threads, snaps, friction, etc.).
- the syringe 3 is held in the housing 2 and supported at its proximal end therein by a syringe support 15 further described below.
- the autoinjector 1 further comprises a protective needle sheath 5 that is coupled to the needle 4 .
- the protective needle sheath 5 is removably coupled to the needle 4 .
- the protective needle sheath 5 may be a rubber needle sheath or a rigid needle sheath which is composed of rubber and a full or partial plastic shell.
- a stopper 6 is arranged for sealing the syringe 3 in a proximal direction P and for displacing the medicament M contained in the syringe 3 through the needle 4 .
- the autoinjector 1 further comprises a sleeve-shaped needle shroud 7 .
- the needle shroud 7 is telescopically coupled to the housing 2 and movable between an extended position relative to the housing 2 in which the needle 4 is covered and a retracted position relative to the housing 2 in which the needle 4 is exposed.
- a shroud spring 8 is arranged to bias the needle shroud 7 in a distal direction D against the housing 2 .
- a drive spring 9 in the shape of a compression spring is arranged within a proximal part of the housing 2 , in particular the rear part 2 . 2 .
- a plunger 10 serves for forwarding the force of the drive spring 9 to the stopper 6 .
- the plunger 10 is hollow and the drive spring 9 is arranged within the plunger 10 , biasing the plunger 10 in the distal direction D against the rear part 2 . 2 .
- the plunger 10 may be solid and the drive 9 may engage a proximal end of the plunger 10 .
- the drive spring 9 could be wrapped around the outer diameter of the plunger 10 and extend within the syringe 3 .
- the autoinjector 1 comprises a cap 11 that may be removably disposed at a distal end of the housing 2 , in particular at a distal end of the front part 2 . 1 .
- the cap 11 may comprise grip features 11 . 1 for facilitating removal of the cap 11 , e.g., by twisting and/or pulling the cap 11 off the case 2 .
- the cap 11 may further include a grip element 11 . 2 , e.g., a barb, a hook, a narrowed section, etc., arranged to engage the protective needle sheath 5 , the housing 2 and/or the needle shroud 7 .
- the protective needle sheath 5 is coupled to the cap 11 in a manner that when the cap 11 is removed, the protective needle sheath 5 is also removed from the needle 4 .
- a plunger release mechanism 12 is arranged for preventing release of the plunger 10 prior to depression of the needle shroud 7 and for releasing the plunger 10 once the needle shroud 7 is sufficiently depressed.
- the autoinjector 1 further comprises at least one audible indicator 13 for producing an audible feedback for a user or patient indicating that medicament delivery is complete.
- the audible indicator 13 is adapted to indicate to a user or a patient that the full dose of medicament M was spent.
- the audible indicator 13 is formed for example as a bistable spring and is held in the rear part 2 . 2 .
- the autoinjector 1 comprises a carrier 16 adapted to mount and hold the syringe 3 within the housing 2 in a forward or distal direction D.
- a shroud pre-lock mechanism 14 is arranged to prevent depression of the needle shroud 7 when the cap 11 is in place, thus avoiding unintentional activation of the autoinjector 1 , e.g. if dropped, during shipping or packaging, etc.
- syringes 3 may have variable lengths L.
- a flange 3 . 1 of the syringe 3 protrudes the carrier 16 in the proximal direction P.
- the syringe support 15 comprises one or more flexible portions 15 . 1 axially biased to accommodate to syringes 3 having different lengths L.
- the flexible portions 15 . 1 are adapted to axially bias the syringe 3 in the distal direction D within the housing 2 and to compensate the variations in length L of the syringe 3 in the distal direction D.
- the syringe support 15 is adapted to accommodate the length L of the syringe 3 of maximum 5% or 3%.
- the syringe support 15 accommodates +/ ⁇ 1.5 mm of the length L for a syringe 3 of 50 mm in length L.
- FIGS. 2 and 3 are schematic views of the rear part 2 . 2 of the housing 2 .
- the rear part 2 . 2 comprises the syringe support 15 .
- the syringe support 15 is adapted to compensate variations in length L of the syringe 3 .
- the syringe support 15 comprises two projecting portions 15 . 3 projecting in the distal direction D and, at its front or distal end, two flexible portions 15 . 1 .
- the flexible portions 15 . 1 adjoin the projecting portions 15 . 3 axially in the distal direction D.
- the flexible portions 15 . 1 are integrally formed with the projecting portions 15 . 3 .
- the projecting portions 15 . 3 are part of the housing 2 , namely of the rear part 2 . 2 .
- the projecting portions 15 . 3 project from a proximal end 2 . 4 of the housing 2 inwardly in the distal direction D.
- the rear part 2 . 2 has the proximal end 2 . 4 .
- the proximal end 2 . 4 of the rear part 2 . 2 is larger than a proximal aperture 2 . 6 so that the proximal end 2 . 4 rests on the edge of the proximal aperture 2 . 6 of the front part 2 . 1 .
- the projecting portions 15 . 3 of the syringe support 15 form part of the housing 2 , namely two rigid arms 2 . 3 , which are extended from the proximal end 2 . 4 inwards into the distal direction D.
- the flexible portions 15 . 1 are arranged on the distal end of the rear part 2 . 2 .
- the rear part 2 . 2 comprises a housing lock 17 having two housing lock arms 17 . 1 to attach the rear part 2 . 2 to the front part 2 . 1 .
- the housing lock arms 17 . 1 are located proximally on the syringe support 15 .
- the housing lock 17 has an outer diameter larger than an outer diameter of the projecting portion 15 . 3 in a biased state.
- the housing lock arms 17 . 1 are being deflectable inwards until they reach corresponding slots 2 . 7 in the front part 2 . 1 in which the housing lock arms 17 . 1 deflect outwards and latch.
- the housing lock arms 17 . 1 are arranged on a proximal section of the rear part 2 . 2 and are biased radially outwards.
- proximal end 2 . 4 of the rear part 2 . 2 forms the proximal end 15 . 6 of the syringe support 15 and has an outer diameter larger than an outer diameter of the projecting portion 15 . 3 .
- the flexible portions 15 . 1 are designed as elastic spring portions.
- the flexible portions 15 . 1 have a progressive spring characteristic curve in respect of an axial deflection such that a progressively increasing spring force in the flexible portions 15 . 1 occurs with increasing length L of the assembled syringe 3 .
- the flexible portions 15 . 1 compensate variations in lengths L of the syringe 3 due to its axial deflection.
- each flexible portion 15 . 1 is attached to the corresponding projecting portion 15 . 3 .
- the opposite distal end is a free end.
- the flexible portions 15 . 1 may be formed from resilient material, e.g. plastic.
- the flexible portions 15 . 1 have a labyrinth-shaped design with at least two axially arranged chambers 15 . 2 connected by at least one web 15 . 4 .
- the distal end of the flexible portions 15 . 1 have at least two supporting ribs 15 . 5 which attach the flange 3 . 1 of the syringe 3 when the syringe 3 is assembled into the syringe carrier 16 and the flange 3 . 1 protrudes the syringe carrier 16 in the proximal direction P (see FIG. 10 ).
- FIG. 4 shows an alternative embodiment of a syringe support 15 ′ formed as a separate single part and the rear part 2 . 2 formed as a separate single part.
- the syringe support 15 ′ has a proximal support end 15 . 6 from which the rigid projecting portions 15 . 3 comprising the flexible portions 15 . 1 distally protrude.
- the proximal support end 15 . 6 and the housing 2 are correspondingly adapted to retain and hold the syringe support 15 ′ in place on the housing 2 , e.g. by securing a rim in a nut or in clips on the housing 2 (shown in dotted line).
- the separate rear part 2 . 2 only comprises the housing lock 17 for releasably connecting the rear part 2 . 2 with the front part 2 . 1 to form the housing 2 .
- FIG. 5 is a schematic longitudinal section view of the rear part 2 . 2 .
- the FIG. 5 shows the rear part 2 . 2 with one flexible portion 15 . 1 that are part of the syringe support 15 .
- the flexible portion 15 . 1 is arranged on a distal section of the rear part 2 . 2 and axially biases the syringe 3 in the distal direction D.
- the housing lock arms 17 . 1 attach the rear part 2 . 2 onto the front part 2 . 1 .
- the housing lock arms 17 . 1 are proximally arranged on the rear part 2 . 2 and are biased radially outwards.
- the housing lock arms 17 . 1 retain the rear part 2 . 2 in position with the front part 2 . 1 .
- FIG. 6 is a schematic side view of the rear part 2 . 2 comprising the syringe support 15 .
- the rear part 2 . 2 comprises an inner stamp 2 . 5 .
- the inner stamp 2 . 5 further supports the assembling and arrangement of the drive spring 9 (see FIG. 1 ).
- FIGS. 7A to 7C are a schematic view of different embodiments of the flexible portion 15 . 1 of the syringe support 15 .
- the flexible portions 15 . 1 are biased axially in the distal direction D.
- FIG. 7A shows a possible embodiment.
- the flexible portion 15 . 1 is designed as a bellow comprising two chambers 15 . 2 which are connected by two webs 15 . 4 .
- the outer surfaces of the flexible portion 15 . 1 namely the proximal surface attached to the projecting portion 15 . 3 and the distal surface of the free end, are flat.
- two ribs 15 . 5 are located which press against the syringe flange 3 . 1 in the assembled state to provide a secure axial support and positioning of the syringe 3 relative to the housing 2 in the distal direction D.
- the flexible portion 15 . 1 is adapted to provide an axial force on the syringe flange 3 . 1 and to axially bias the syringe 3 in the distal direction D.
- the flexible portion 15 . 1 namely the bellow, is axially deflected and stressed so that the variable lengths L of the syringes 3 can be compensated and an axial movement of the syringe 3 is prevented during storage, transportation, drop, and use.
- FIG. 7B shows an alternative embodiment of the flexible portion 15 . 1 designed as a bellow with one chamber 15 . 2 and bent webs 15 . 4 coupling the chamber 15 . 2 and the projecting portion 15 . 3 .
- Supporting ribs 15 . 5 are attached at the distal end.
- FIG. 7C shows a further embodiment of the flexible portion 15 . 1 of a meander-shaped form with a bent flexural beam 15 . 7 running in a meander-shaped manner and with connecting webs 15 . 4 and supporting ribs 15 . 5 .
- the flexible portions 15 . 1 may be designed in the form of a multiply folded or bent arc or half-arc, or in the form of a spring arm. Furthermore, the flexible portions 15 . 1 may be of an accordion-shaped, labyrinth-shaped, U-shaped, V-shaped, W-shaped, or S-shaped design.
- the flexible portion 15 . 1 of the syringe support 15 allows compensation of length tolerances of syringes 3 to be assembled as described above.
- FIG. 8 is a schematic side view of the rear part 2 . 2 with the flexible portion 15 . 1 arranged on the distal end of the rear part 2 . 2 .
- the proximal end of the flexible portion 15 . 1 is attached to the projecting portion 15 . 3 and the distal end of the flexible portion 15 . 1 is formed as a free end axially biased.
- FIG. 9 shows the front part 2 . 1 and the rear part 2 . 2 of the housing 2 .
- the front part 2 . 1 and the rear part 2 . 2 are correspondingly adapted to couple with each other, e.g. by means of a releasable connection formed by e.g. the housing locking arms 17 . 1 and corresponding slots 2 . 7 .
- FIG. 10 shows the syringe support 15 and the syringe 3 in an assembled state.
- the supporting ribs 15 . 5 attach the flange 3 . 1 of the syringe 3 when the syringe 3 is assembled into the syringe carrier 16 (the syringe carrier 16 is only illustrated in FIG. 1 ).
- a drug or medicament can include at least one small or large molecule, or combinations thereof, in various types of formulations, for the treatment of one or more diseases.
- exemplary pharmaceutically active compounds may include small molecules; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more of these drugs are also contemplated.
- a drug delivery device shall encompass any type of device or system configured to dispense a drug into a human or animal body.
- a drug delivery device may be an injection device (e.g., syringe, pen injector, auto injector, large-volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal or pulmonary), implantable (e.g., coated stent, capsule), or feeding systems for the gastro-intestinal tract.
- the presently described drugs may be particularly useful with injection devices that include a needle, e.g., a small gauge needle.
- the drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device.
- the drug container may be, e.g., a cartridge, syringe, reservoir, or other vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more pharmaceutically active compounds.
- the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days).
- the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20° C.), or refrigerated temperatures (e.g., from about ⁇ 4° C. to about 4° C.).
- the drug container may be or may include a dual-chamber cartridge configured to store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs) separately, one in each chamber.
- the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components of the drug or medicament prior to and/or during dispensing into the human or animal body.
- the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing.
- the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
- the drug delivery devices and drugs described herein can be used for the treatment and/or prophylaxis of many different types of disorders.
- exemplary disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism.
- Further exemplary disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.
- ACS acute coronary syndrome
- angina myocardial infarction
- cancer macular degeneration
- inflammation hay fever
- atherosclerosis and/or rheumatoid arthritis.
- Exemplary drugs for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
- the term “derivative” refers to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness).
- Exemplary insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Exemplary insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-
- GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example: Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993 (a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide/Victoza, Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP
- An exemplary oligonucleotide is, for example: mipomersen/Kynamro, a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.
- DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
- hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Nafarelin
- Goserelin Goserelin.
- Exemplary polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- An example of a hyaluronic acid derivative is Hylan G-F 20/Synvisc, a sodium hyaluronate.
- antibody refers to an immunoglobulin molecule or an antigen-binding portion thereof.
- antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab′) 2 fragments, which retain the ability to bind antigen.
- the antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody.
- the antibody has effector function and can fix complement.
- the antibody has reduced or no ability to bind an Fc receptor.
- the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
- fragment refers to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen.
- Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments.
- Antibody fragments that are useful include, for example, Fab fragments, F(ab′)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
- CDR complementarity-determining region
- framework region refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding.
- framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
- Exemplary antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
- anti PCSK-9 mAb e.g., Alirocumab
- anti IL-6 mAb e.g., Sarilumab
- anti IL-4 mAb e.g., Dupilumab
- the compounds described herein may be used in pharmaceutical formulations comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier.
- the compounds may also be used in pharmaceutical formulations that include one or more other active pharmaceutical ingredients or in pharmaceutical formulations in which the present compound or a pharmaceutically acceptable salt thereof is the only active ingredient.
- the pharmaceutical formulations of the present disclosure encompass any formulation made by admixing a compound described herein and a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable salts of any drug described herein are also contemplated for use in drug delivery devices.
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCl or HBr salts.
- Basic salts are e.g. salts having a cation selected from an alkali or alkaline earth metal, e.g.
- R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates or alkanolates such as methanolates or ethanolates.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The disclosure relates to a syringe support for supporting an axial position of a syringe relative to a housing of an autoinjector. The syringe support comprises a projecting portion, which projects from the syringe support in a distal direction and a flexible portion which axially adjoins the projecting portion. The flexible portion is adapted to axially bias the syringe in the distal direction within the housing. The disclosure further relates to an autoinjector.
Description
- The present application is a continuation application of U.S. patent application Ser. No. 17/666,696, filed on Feb. 8, 2022, which is a continuation application of U.S. patent application Ser. No. 15/579,146, filed on Dec. 1, 2017, which is the national stage entry of International Patent Application No. PCT/EP2016/062461, filed on Jun. 2, 2016, and claims priority to Application No. EP 15170596.9, filed on Jun. 3, 2015, the disclosures of which are expressly incorporated herein in entirety by reference thereto.
- The disclosure relates to a syringe support and to an autoinjector.
- Administering an injection is a process that presents a number of mental and physical risks and challenges for users and healthcare professionals. Injection devices typically fall into two categories—manual devices and autoinjectors. In a conventional manual device, manual force is required to drive a medicament through a needle. This is typically done by a plunger that has to be continuously pressed during the injection. There are numerous disadvantages associated with this approach. For example, if the plunger is released prematurely, the injection will stop and may not deliver an intended dose. Furthermore, the force required to push the plunger may be too high (e.g., if the user is elderly or a child). Additionally, aligning the injection device, administering the injection, and keeping the injection device still during the injection may require dexterity which some patients may not have.
- Autoinjector devices may be single-use or reusable devices and aim to make self-injection easier for patients. A conventional autoinjector may completely or partially replace activities involved in parenteral drug delivery from a manual device. Typically, such activities include removal of a protective syringe cap, insertion of the needle, providing the force for administering the injection and possibly removal and shielding of the used needle.
- There remains a need for a syringe support within the autoinjector and an improved autoinjector comprising such a syringe support so that the autoinjector and its components, in particular a syringe, are securely arranged within a housing.
- One aspect of the present disclosure relates to a syringe support for supporting an axial position of a syringe relative to a housing of an autoinjector, wherein the syringe support comprises a projecting portion which projects from the syringe support into a distal direction and a flexible portion which axially adjoins the projecting portion and which is adapted to axially bias the syringe in the distal direction within the housing.
- The syringe support provides a secure arrangement of the syringe within the housing. In particular, the syringe is arranged within the housing less prone to failures and damages and allows tolerance compensation. The syringe support further ensures that the syringe is biased forward against forward stop and thereby ensures that the needle is always inserted to full insertion depth. In particular, the syringe does not move backward under force of piercing skin. Furthermore, the syringe support allows that syringes with different lengths due to manufacturing tolerances may be arranged within the same housing.
- In an exemplary embodiment, the flexible portion is adapted to accommodate to syringes having different lengths. In other words, the flexible portion provides a secure arrangement by compensating different syringe lengths. In particular, the flexible portion is adapted to compensate variations in length of the syringe of maximum 5%, in particular 3%. For example, the syringe support accommodates +/−1.5 mm syringe length for a syringe of 50 mm in length.
- On final assembly of the syringe into a housing of an autoinjector, after the syringe has been inserted and moved to its final assembling position inside the housing, the flexible portion, also called compliant backstop, deflects axially and thus provides an axial force on the syringe to bias it forward and so prevents its axial movement during storage, transportation, drop and use. The flexible portion is sized to accommodate the tolerances of both the syringe and the autoinjector, in particular the housing, whilst limiting the movement of the syringe during drop to prevent accidental de-booting of the syringe. The stiffness of the flexible portion is tailored to provide a minimum force required to restrain the syringe during storage, transportation, drop, and use so as to not unduly stress the syringe flange and for example risk glass fracture.
- In an exemplary embodiment, the flexible portion is designed in the form of a web, in the form of a flexure beam or in the form of a spring arm. Moreover, the flexible portion is of meander-shaped, accordion-shaped, labyrinth-shaped, U-shaped, V-shaped, W-shaped or S-shaped design. In particular, the flexible portion is of an accordion-shaped or labyrinth-shaped design to be maintained in a relaxed position and to form a stop for the syringe for compensating different syringe lengths. Furthermore, the flexible portion may be stressed during assembling of the syringe due to different lengths of the syringes to avoid or at least minimize risk of damages. For instance, during assembling, the syringe is carried and holds by a syringe carrier at its distal end wherein the proximal end, namely the flange, of the syringe projects the proximal end of the syringe carrier so that the flexible portion, engaging the flange, deflects and further stresses axially rearwards so that the length of the syringe can be compensated.
- Furthermore, the flexible portion may be formed from resilient material. The flexible portion is designed to provide a reasonable compressive strength as well as a bending strength. In particular, the flexible portion may be formed from a corresponding resilient material, e.g. plastic, and/or with a corresponding structural design, e.g. horizontal and vertical webs and ribs. Furthermore, the projecting portion is stronger than the flexible portion, e.g. the plastic of the projecting portion is stronger than the plastic of the flexible portion.
- Moreover, the resilient flexible portion could be in the form of a multiply bent arc of resilient material, wherein at least one end of the multiply bent arc is attached to the syringe support and an outer free end of the multiply bent arc is in juxtaposition with the flange of the syringe. The flexible portion axially extends in the distal direction.
- In an exemplary embodiment, the flexible portion is located distally on the syringe support. Thereby, the distal flexible portion retains the syringe in position. The distal end of the distal flexible portion is a free end. The opposite proximal end of the distal flexible portion adjoins the projecting portion. Furthermore, more than one flexible portion may be arranged around the circumference of the syringe flange, thus the syringe is reliably held in position.
- Moreover, the flexible portion is integrally formed with the projecting portion so that the flexible portion deflects axially rearwards against the projecting portion when the syringe is assembled or moves rearwards. In particular, the flexible portion may be integrally moulded with the syringe support for ease of manufacture, e.g. may be produced in an injection moulding die by injection moulding from plastic.
- Furthermore, the syringe support may comprise a number of projecting portions with adjoined flexible portions that interact with the flange of the syringe for providing length compensation or a damping and a restricting of an axial movement of smaller syringes rearwards when the syringe is assembled and in place within the housing. Furthermore, the flexible portions may be arranged around the circumference of the syringe flange, thus the syringe is reliably held in position.
- In a further embodiment, at least two flexible portions are arranged distally on the syringe support. The at least two flexible portions are arranged opposed to each other. More than two flexible portions may be provided and may be symmetrically arranged on the syringe support. The flexible portions are adapted to provide a secure axial support and positioning of the syringe relative to the housing in the rearward direction. Thus, a risk of breakage is reduced.
- According to another aspect of the disclosure, an autoinjector comprises a syringe support as described above and a housing, wherein the housing comprises such a syringe support.
- In an assembled state, the flexible portion and the flange of the syringe contact one another and are pressed onto one another so that the syringe is securely positioned.
- In an exemplary embodiment, the flexible portion is distally attached to the projecting portion. In particular, the flexible portion is biased in the distal direction.
- In an exemplary embodiment, the syringe support comprises at least two rigid projecting portions, e.g. rigid arms, wherein each rigid arm comprises one flexible portion. In particular, the two rigid arms are formed as inner arms which inwardly extend from a proximal outer housing part, e.g. a proximal end, into the housing.
- In particular, the housing comprises a front part and a rear part wherein the flexible portion is arranged on the rear part. The rear part comprises a proximal end from which the rigid arms are inwardly extended. In this way, the flexible portion is arranged on a distal end of the rigid arms.
- Furthermore, the housing comprises a proximal end which is larger than a proximal aperture of the housing. Thereby, the proximal end of the rear part rests on the edge of the proximal aperture of the front part to proximally close the housing.
- Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating exemplary embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
- The present invention will become more fully understood from the detailed description given herein below and the accompanying drawings which are given by way of illustration only, and thus, are not limitative of the present invention.
-
FIG. 1 is a schematic perspective partial section of an exemplary embodiment of an autoinjector, -
FIG. 2 is a schematic perspective view of an exemplary embodiment of a housing part comprising a syringe support from an inner end, -
FIG. 3 is a schematic perspective view of an exemplary embodiment of a housing part comprising a syringe support from a proximal end, -
FIG. 4 is a schematic perspective view of an exemplary embodiment of a separate single syringe support and a separate single rear part, -
FIG. 5 is a schematic longitudinal section view of an exemplary embodiment of a housing part having a syringe support, -
FIG. 6 is a schematic side view of a housing part having a syringe support, -
FIG. 7A to 7C is a schematic view of different exemplary embodiments of a flexible portion of a syringe support, -
FIG. 8 is a schematic side view of an exemplary embodiment of a housing part having a syringe support, -
FIG. 9 is an explosion view of a rear part and a front part of a housing and -
FIG. 10 is a schematic perspective view of an exemplary embodiment of a syringe support and a syringe in an assembled state. - Corresponding parts are marked with the same reference symbols in all figures.
-
FIG. 1 is a schematic perspective partial section of an exemplary embodiment of an autoinjector 1 in a state after assembly. - The autoinjector 1 comprises a
housing 2 including a sleeve-shaped front part 2.1 and a rear part 2.2. Alternatively, thehousing 2 may be formed as a one-piece housing (not shown). - The
housing 2 is adapted to hold asyringe 3, e.g. a glass syringe. Thesyringe 3 may be a pre-filled syringe containing a liquid medicament M and have aneedle 4 arranged on a distal end. In another exemplary embodiment, thesyringe 3 may be a cartridge which includes the medicament M and engages a removable needle (e.g., by threads, snaps, friction, etc.). In the shown exemplary embodiment, thesyringe 3 is held in thehousing 2 and supported at its proximal end therein by asyringe support 15 further described below. - The autoinjector 1 further comprises a
protective needle sheath 5 that is coupled to theneedle 4. For example, theprotective needle sheath 5 is removably coupled to theneedle 4. Theprotective needle sheath 5 may be a rubber needle sheath or a rigid needle sheath which is composed of rubber and a full or partial plastic shell. - A
stopper 6 is arranged for sealing thesyringe 3 in a proximal direction P and for displacing the medicament M contained in thesyringe 3 through theneedle 4. - The autoinjector 1 further comprises a sleeve-shaped
needle shroud 7. In an exemplary embodiment, theneedle shroud 7 is telescopically coupled to thehousing 2 and movable between an extended position relative to thehousing 2 in which theneedle 4 is covered and a retracted position relative to thehousing 2 in which theneedle 4 is exposed. Furthermore, ashroud spring 8 is arranged to bias theneedle shroud 7 in a distal direction D against thehousing 2. - A drive spring 9 in the shape of a compression spring is arranged within a proximal part of the
housing 2, in particular the rear part 2.2. Aplunger 10 serves for forwarding the force of the drive spring 9 to thestopper 6. In an exemplary embodiment, theplunger 10 is hollow and the drive spring 9 is arranged within theplunger 10, biasing theplunger 10 in the distal direction D against the rear part 2.2. In another exemplary embodiment, theplunger 10 may be solid and the drive 9 may engage a proximal end of theplunger 10. Likewise, the drive spring 9 could be wrapped around the outer diameter of theplunger 10 and extend within thesyringe 3. - Furthermore, the autoinjector 1 comprises a
cap 11 that may be removably disposed at a distal end of thehousing 2, in particular at a distal end of the front part 2.1. Thecap 11 may comprise grip features 11.1 for facilitating removal of thecap 11, e.g., by twisting and/or pulling thecap 11 off thecase 2. Thecap 11 may further include a grip element 11.2, e.g., a barb, a hook, a narrowed section, etc., arranged to engage theprotective needle sheath 5, thehousing 2 and/or theneedle shroud 7. For example, theprotective needle sheath 5 is coupled to thecap 11 in a manner that when thecap 11 is removed, theprotective needle sheath 5 is also removed from theneedle 4. - A
plunger release mechanism 12 is arranged for preventing release of theplunger 10 prior to depression of theneedle shroud 7 and for releasing theplunger 10 once theneedle shroud 7 is sufficiently depressed. - In an exemplary embodiment, the autoinjector 1 further comprises at least one
audible indicator 13 for producing an audible feedback for a user or patient indicating that medicament delivery is complete. In other words: Theaudible indicator 13 is adapted to indicate to a user or a patient that the full dose of medicament M was spent. Theaudible indicator 13 is formed for example as a bistable spring and is held in the rear part 2.2. - To allow an accurate support of the
syringe 3 during and after assembly, the autoinjector 1 comprises acarrier 16 adapted to mount and hold thesyringe 3 within thehousing 2 in a forward or distal direction D. - A
shroud pre-lock mechanism 14 is arranged to prevent depression of theneedle shroud 7 when thecap 11 is in place, thus avoiding unintentional activation of the autoinjector 1, e.g. if dropped, during shipping or packaging, etc. - Due to manufacturing tolerance,
syringes 3 may have variable lengths L. Thus, a flange 3.1 of thesyringe 3 protrudes thecarrier 16 in the proximal direction P. To support the axial position of thesyringe 3 relative to thehousing 2 after assembly, in particular during storage, transportation and normal use, thesyringe support 15 comprises one or more flexible portions 15.1 axially biased to accommodate tosyringes 3 having different lengths L. The flexible portions 15.1 are adapted to axially bias thesyringe 3 in the distal direction D within thehousing 2 and to compensate the variations in length L of thesyringe 3 in the distal direction D. In particular, thesyringe support 15 is adapted to accommodate the length L of thesyringe 3 of maximum 5% or 3%. For example, thesyringe support 15 accommodates +/−1.5 mm of the length L for asyringe 3 of 50 mm in length L. -
FIGS. 2 and 3 are schematic views of the rear part 2.2 of thehousing 2. The rear part 2.2 comprises thesyringe support 15. Thesyringe support 15 is adapted to compensate variations in length L of thesyringe 3. In detail, thesyringe support 15 comprises two projecting portions 15.3 projecting in the distal direction D and, at its front or distal end, two flexible portions 15.1. The flexible portions 15.1 adjoin the projecting portions 15.3 axially in the distal direction D. - The flexible portions 15.1 are integrally formed with the projecting portions 15.3. In the shown embodiment, the projecting portions 15.3 are part of the
housing 2, namely of the rear part 2.2. - The projecting portions 15.3 project from a proximal end 2.4 of the
housing 2 inwardly in the distal direction D. - In the shown embodiment, the rear part 2.2 has the proximal end 2.4. The proximal end 2.4 of the rear part 2.2 is larger than a proximal aperture 2.6 so that the proximal end 2.4 rests on the edge of the proximal aperture 2.6 of the front part 2.1.
- The projecting portions 15.3 of the
syringe support 15 form part of thehousing 2, namely two rigid arms 2.3, which are extended from the proximal end 2.4 inwards into the distal direction D. The flexible portions 15.1 are arranged on the distal end of the rear part 2.2. - Furthermore, the rear part 2.2 comprises a
housing lock 17 having two housing lock arms 17.1 to attach the rear part 2.2 to the front part 2.1. The housing lock arms 17.1 are located proximally on thesyringe support 15. For secure fastening of the rear part 2.2 to the front part 2.1, thehousing lock 17 has an outer diameter larger than an outer diameter of the projecting portion 15.3 in a biased state. - For assembling of the rear part 2.2 to the front part 2.1, the housing lock arms 17.1 are being deflectable inwards until they reach corresponding slots 2.7 in the front part 2.1 in which the housing lock arms 17.1 deflect outwards and latch. The housing lock arms 17.1 are arranged on a proximal section of the rear part 2.2 and are biased radially outwards.
- Furthermore, the proximal end 2.4 of the rear part 2.2 forms the proximal end 15.6 of the
syringe support 15 and has an outer diameter larger than an outer diameter of the projecting portion 15.3. - The flexible portions 15.1 are designed as elastic spring portions. The flexible portions 15.1 have a progressive spring characteristic curve in respect of an axial deflection such that a progressively increasing spring force in the flexible portions 15.1 occurs with increasing length L of the assembled
syringe 3. Thus, the flexible portions 15.1 compensate variations in lengths L of thesyringe 3 due to its axial deflection. - One end of each flexible portion 15.1 is attached to the corresponding projecting portion 15.3. The opposite distal end is a free end. The flexible portions 15.1 may be formed from resilient material, e.g. plastic.
- In the shown embodiment, the flexible portions 15.1 have a labyrinth-shaped design with at least two axially arranged chambers 15.2 connected by at least one web 15.4. The distal end of the flexible portions 15.1 have at least two supporting ribs 15.5 which attach the flange 3.1 of the
syringe 3 when thesyringe 3 is assembled into thesyringe carrier 16 and the flange 3.1 protrudes thesyringe carrier 16 in the proximal direction P (seeFIG. 10 ). -
FIG. 4 shows an alternative embodiment of asyringe support 15′ formed as a separate single part and the rear part 2.2 formed as a separate single part. Thesyringe support 15′ has a proximal support end 15.6 from which the rigid projecting portions 15.3 comprising the flexible portions 15.1 distally protrude. The proximal support end 15.6 and thehousing 2, in particular the front part 2.1 or the rear part 2.2, are correspondingly adapted to retain and hold thesyringe support 15′ in place on thehousing 2, e.g. by securing a rim in a nut or in clips on the housing 2 (shown in dotted line). - The separate rear part 2.2 only comprises the
housing lock 17 for releasably connecting the rear part 2.2 with the front part 2.1 to form thehousing 2. -
FIG. 5 is a schematic longitudinal section view of the rear part 2.2. TheFIG. 5 shows the rear part 2.2 with one flexible portion 15.1 that are part of thesyringe support 15. The flexible portion 15.1 is arranged on a distal section of the rear part 2.2 and axially biases thesyringe 3 in the distal direction D. - The housing lock arms 17.1 attach the rear part 2.2 onto the front part 2.1. The housing lock arms 17.1 are proximally arranged on the rear part 2.2 and are biased radially outwards. The housing lock arms 17.1 retain the rear part 2.2 in position with the front part 2.1.
-
FIG. 6 is a schematic side view of the rear part 2.2 comprising thesyringe support 15. To guide the rear part 2.2 during assembling and to support it after assembling and during use, the rear part 2.2 comprises an inner stamp 2.5. The inner stamp 2.5 further supports the assembling and arrangement of the drive spring 9 (seeFIG. 1 ). -
FIGS. 7A to 7C are a schematic view of different embodiments of the flexible portion 15.1 of thesyringe support 15. The flexible portions 15.1 are biased axially in the distal direction D. -
FIG. 7A shows a possible embodiment. The flexible portion 15.1 is designed as a bellow comprising two chambers 15.2 which are connected by two webs 15.4. - The outer surfaces of the flexible portion 15.1, namely the proximal surface attached to the projecting portion 15.3 and the distal surface of the free end, are flat.
- Further at the distal flat end of the flexible portion 15.1, two ribs 15.5 are located which press against the syringe flange 3.1 in the assembled state to provide a secure axial support and positioning of the
syringe 3 relative to thehousing 2 in the distal direction D. - For assembling
syringes 3 having variable lengths L within thesame housing 2, the flexible portion 15.1 is adapted to provide an axial force on the syringe flange 3.1 and to axially bias thesyringe 3 in the distal direction D. At this, the flexible portion 15.1, namely the bellow, is axially deflected and stressed so that the variable lengths L of thesyringes 3 can be compensated and an axial movement of thesyringe 3 is prevented during storage, transportation, drop, and use. -
FIG. 7B shows an alternative embodiment of the flexible portion 15.1 designed as a bellow with one chamber 15.2 and bent webs 15.4 coupling the chamber 15.2 and the projecting portion 15.3. Supporting ribs 15.5 are attached at the distal end. -
FIG. 7C shows a further embodiment of the flexible portion 15.1 of a meander-shaped form with a bent flexural beam 15.7 running in a meander-shaped manner and with connecting webs 15.4 and supporting ribs 15.5. - Furthermore, the flexible portions 15.1 may be designed in the form of a multiply folded or bent arc or half-arc, or in the form of a spring arm. Furthermore, the flexible portions 15.1 may be of an accordion-shaped, labyrinth-shaped, U-shaped, V-shaped, W-shaped, or S-shaped design.
- The flexible portion 15.1 of the
syringe support 15 allows compensation of length tolerances ofsyringes 3 to be assembled as described above. -
FIG. 8 is a schematic side view of the rear part 2.2 with the flexible portion 15.1 arranged on the distal end of the rear part 2.2. The proximal end of the flexible portion 15.1 is attached to the projecting portion 15.3 and the distal end of the flexible portion 15.1 is formed as a free end axially biased. -
FIG. 9 shows the front part 2.1 and the rear part 2.2 of thehousing 2. The front part 2.1 and the rear part 2.2 are correspondingly adapted to couple with each other, e.g. by means of a releasable connection formed by e.g. the housing locking arms 17.1 and corresponding slots 2.7. -
FIG. 10 shows thesyringe support 15 and thesyringe 3 in an assembled state. The supporting ribs 15.5 attach the flange 3.1 of thesyringe 3 when thesyringe 3 is assembled into the syringe carrier 16 (thesyringe carrier 16 is only illustrated inFIG. 1 ). - The terms “drug” or “medicament” are used herein to describe one or more pharmaceutically active compounds. As described below, a drug or medicament can include at least one small or large molecule, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Exemplary pharmaceutically active compounds may include small molecules; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more of these drugs are also contemplated.
- The term “drug delivery device” shall encompass any type of device or system configured to dispense a drug into a human or animal body. Without limitation, a drug delivery device may be an injection device (e.g., syringe, pen injector, auto injector, large-volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal or pulmonary), implantable (e.g., coated stent, capsule), or feeding systems for the gastro-intestinal tract. The presently described drugs may be particularly useful with injection devices that include a needle, e.g., a small gauge needle.
- The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more pharmaceutically active compounds. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20° C.), or refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components of the drug or medicament prior to and/or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
- The drug delivery devices and drugs described herein can be used for the treatment and/or prophylaxis of many different types of disorders. Exemplary disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further exemplary disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.
- Exemplary drugs for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the term “derivative” refers to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness).
- Exemplary insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Exemplary insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin. Exemplary GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example: Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993 (a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide/Victoza, Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.
- An exemplary oligonucleotide is, for example: mipomersen/Kynamro, a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.
- Exemplary DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
- Exemplary hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
- Exemplary polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20/Synvisc, a sodium hyaluronate.
- The term “antibody”, as used herein, refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab′)2 fragments, which retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
- The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful include, for example, Fab fragments, F(ab′)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
- The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
- Exemplary antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
- The compounds described herein may be used in pharmaceutical formulations comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier. The compounds may also be used in pharmaceutical formulations that include one or more other active pharmaceutical ingredients or in pharmaceutical formulations in which the present compound or a pharmaceutically acceptable salt thereof is the only active ingredient. Accordingly, the pharmaceutical formulations of the present disclosure encompass any formulation made by admixing a compound described herein and a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable salts of any drug described herein are also contemplated for use in drug delivery devices. Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from an alkali or alkaline earth metal, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are known to those of skill in the arts.
- Pharmaceutically acceptable solvates are for example hydrates or alkanolates such as methanolates or ethanolates.
- Those of skill in the art will understand that modifications (additions and/or removals) of various components of the substances, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.
-
-
- 1 autoinjector
- 2 housing
- 2.1 front part
- 2.2 rear part
- 2.3 rigid arm
- 2.4 proximal end
- 2.5 stamp
- 2.6 proximal aperture
- 2.7 slot
- 3 syringe
- 3.1 flange
- 4 needle
- 5 protective needle sheath
- 6 stopper
- 7 needle shroud
- 8 shroud spring
- 9 drive spring
- 10 plunger
- 11 cap
- 11.1 grip feature
- 11.2 grip element
- 12 plunger release mechanism
- 13 audible indicator
- 14 shroud pre-lock mechanism
- 15 syringe support
- 15.1 flexible portion
- 15.2 chamber
- 15.3 projecting portion
- 15.4 web
- 15.5 rib
- 15.6 proximal support end
- 15.7 beam
- 16 carrier
- 17 housing lock
- 17.1 housing lock arm
- D distal direction
- L length
- M medicament
- P proximal direction
Claims (21)
1.-17. (canceled)
18. An auto-injector comprising:
a housing;
a syringe configured to be disposed in the housing, the syringe containing a liquid medicament, the syringe having a distal end configured to hold a needle, and the syringe having a proximal end comprising a flange; and
a syringe support configured to be disposed in the housing proximal to the syringe and configured to be coupled to the housing, the syringe support having a distal end comprising a flexible portion configured to engage a proximal surface of the flange of the syringe to bias the syringe in a distal direction relative to the syringe support and a projecting portion that extends in an axial direction and comprises an outward protrusion configured to axially couple the syringe support to the housing to limit axial movement of the syringe support relative to the housing.
19. The auto-injector of claim 18 , wherein the projecting portion is a first projecting portion, the outward protrusion is a first outward protrusion, and the syringe support comprises a second projecting portion that extends in the axial direction and comprises a second outward protrusion configured to axially couple the syringe support to the housing to limit axial movement of the syringe support relative to the housing.
20. The auto-injector of claim 19 , wherein the syringe support has an opening defined by a first surface of the first projecting portion and a second surface of the second projecting portion.
21. The auto-injector of claim 18 , wherein the flexible portion comprises at least two angled surfaces.
22. The auto-injector of claim 21 , wherein the two angled surfaces have equal and opposite angles with respect to each other and are angled with respect to a longitudinal axis of the housing.
23. The auto-injector of claim 21 , wherein the two angled surfaces define a V-shaped portion.
24. The auto-injector of claim 18 , wherein the flexible portion comprises a web portion.
25. The auto-injector of claim 18 , wherein the syringe support is a unitary structure.
26. The auto-injector of claim 18 , wherein the flexible portion has a flat, distal end.
27. The auto-injector of claim 18 , wherein the flexible portion is configured to flex in an axial direction.
28. The auto-injector of claim 18 , wherein the outward protrusion is located on a proximal portion of the syringe support.
29. The auto-injector of claim 18 , wherein the syringe support is formed from a plastic material and the flexible portion is configured as a spring such that the flexible portion is configured as a resilient plastic spring.
30. The auto-injector of claim 18 , wherein the syringe support is axially separated from a syringe carrier of the auto-injector that is configured to retain the syringe when (i) the syringe is disposed within the syringe carrier, (ii) the syringe carrier is disposed within the housing, and (iii) the syringe support is coupled to the housing and disposed within the housing.
31. The auto-injector of claim 18 , wherein the syringe support is configured to be coupled to a proximal portion of the housing.
32. The auto-injector of claim 18 , wherein the syringe support is configured to be coupled to the housing via a direct coupling between the outward protrusion and the housing.
33. A method comprising:
disposing a syringe within a housing of an auto-injector, the syringe containing a liquid medicament, the syringe having a distal end configured to hold a needle, and the syringe having a proximal end comprising a flange; and
disposing a syringe support within the housing and proximal to the syringe such that (i) a flexible portion located on a distal end of the syringe support engages a proximal surface of the flange of the syringe to bias the syringe in a distal direction relative to the syringe support and (ii) an outward protrusion located on an axially projecting portion axially couples the syringe support to the housing to limit axial movement of the syringe support relative to the housing.
34. The method of claim 33 , wherein the flexible portion comprises a web portion, and at least two angled surfaces that have equal and opposite angles with respect to each other and define a V-shaped portion.
35. The method of claim 33 , wherein disposing the syringe support within the housing comprises engaging a flat, distal end of the flexible portion to the proximal surface of the flange of the syringe.
36. The method of claim 33 , wherein disposing the syringe support within the housing comprises flexing the flexible portion in an axial direction.
37. The method of claim 33 , wherein disposing the syringe support within the housing comprises directly coupling the outward protrusion to the housing to axially couple the syringe support to the housing to limit axial movement of the syringe support relative to the housing.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/738,644 US20220370717A1 (en) | 2015-06-03 | 2022-05-06 | Syringe support and autoinjector |
US18/106,278 US11752266B2 (en) | 2015-06-03 | 2023-02-06 | Syringe support and autoinjector |
US18/413,701 US12042636B2 (en) | 2015-06-03 | 2024-01-16 | Syringe support and autoinjector |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15170596.9 | 2015-06-03 | ||
EP15170596 | 2015-06-03 | ||
PCT/EP2016/062461 WO2016193355A1 (en) | 2015-06-03 | 2016-06-02 | Syringe support and autoinjector |
US201715579146A | 2017-12-01 | 2017-12-01 | |
US17/666,696 US11400216B2 (en) | 2015-06-03 | 2022-02-08 | Syringe support and autoinjector |
US17/738,644 US20220370717A1 (en) | 2015-06-03 | 2022-05-06 | Syringe support and autoinjector |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/666,696 Continuation US11400216B2 (en) | 2015-06-03 | 2022-02-08 | Syringe support and autoinjector |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/106,278 Continuation US11752266B2 (en) | 2015-06-03 | 2023-02-06 | Syringe support and autoinjector |
US18/413,701 Continuation US12042636B2 (en) | 2015-06-03 | 2024-01-16 | Syringe support and autoinjector |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220370717A1 true US20220370717A1 (en) | 2022-11-24 |
Family
ID=53276821
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/579,146 Active 2037-04-20 US11266782B2 (en) | 2015-06-03 | 2016-06-02 | Syringe support and autoinjector |
US17/666,696 Active US11400216B2 (en) | 2015-06-03 | 2022-02-08 | Syringe support and autoinjector |
US17/738,644 Pending US20220370717A1 (en) | 2015-06-03 | 2022-05-06 | Syringe support and autoinjector |
US18/106,278 Active US11752266B2 (en) | 2015-06-03 | 2023-02-06 | Syringe support and autoinjector |
US18/413,701 Active US12042636B2 (en) | 2015-06-03 | 2024-01-16 | Syringe support and autoinjector |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/579,146 Active 2037-04-20 US11266782B2 (en) | 2015-06-03 | 2016-06-02 | Syringe support and autoinjector |
US17/666,696 Active US11400216B2 (en) | 2015-06-03 | 2022-02-08 | Syringe support and autoinjector |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/106,278 Active US11752266B2 (en) | 2015-06-03 | 2023-02-06 | Syringe support and autoinjector |
US18/413,701 Active US12042636B2 (en) | 2015-06-03 | 2024-01-16 | Syringe support and autoinjector |
Country Status (14)
Country | Link |
---|---|
US (5) | US11266782B2 (en) |
EP (1) | EP3302635A1 (en) |
JP (1) | JP6856549B2 (en) |
KR (2) | KR102614624B1 (en) |
CN (2) | CN117085210A (en) |
AR (1) | AR104873A1 (en) |
AU (1) | AU2016269707B2 (en) |
BR (1) | BR112017025749B1 (en) |
HK (1) | HK1249456A1 (en) |
IL (1) | IL256011A (en) |
MX (1) | MX2017015511A (en) |
RU (1) | RU2720168C2 (en) |
TW (1) | TW201707738A (en) |
WO (1) | WO2016193355A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12042636B2 (en) | 2015-06-03 | 2024-07-23 | Sanofi-Aventis Deutschland Gmbh | Syringe support and autoinjector |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210016554A (en) | 2018-05-24 | 2021-02-16 | 노파르티스 아게 | Automatic drug delivery device |
KR102651644B1 (en) | 2019-07-18 | 2024-03-27 | 에스에이치엘 메디컬 아게 | Support structures, drug delivery devices, and assembly methods |
IL312187A (en) | 2021-10-20 | 2024-06-01 | Regeneron Pharma | Methods for treating prurigo nodularis by administering an il-4r antagonist |
WO2023130010A1 (en) | 2021-12-30 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
TW202406572A (en) | 2022-05-02 | 2024-02-16 | 美商再生元醫藥公司 | Anti-interleukin-4 receptor (il-4r) antibody formulations |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
US20240025978A1 (en) | 2022-06-24 | 2024-01-25 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
US20240034798A1 (en) | 2022-07-08 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis by administering an il-4r antagonist |
WO2024094705A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Drug delivery device having a two-part user indicator |
WO2024094699A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Container holder and drug delivery device comprising the container holder |
WO2024094706A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Audible indicator, indicator holder and method of assembling an audible indicator |
WO2024094707A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Drug delivery device with feedback element and method for providing a user of a drug delivery device feedback regarding a dose dispensing process |
WO2024094700A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Method for assembling an assembly for a drug delivery device and drug delivery device. |
WO2024094704A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Arrangement for a drug delivery device, drug delivery device and method for assembly |
WO2024094701A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Assembly for a drug delivery device |
WO2024094703A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Plunger for expelling a drug, drug delivery device, rear sub-assembly and corresponding methods |
WO2024094698A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Front sub-assembly for a drug delivery device |
WO2024094702A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Device body for a drug delivery device, assembly for a drug delivery device and drug delivery device |
US20240141051A1 (en) | 2022-11-01 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
Family Cites Families (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB743839A (en) | 1953-02-22 | 1956-01-25 | Hubert Percival Schofield | Improvements in or relating to devices for dispensing or delivering predetermined quantities of liquids from cartridges or the like containers |
US4964866A (en) | 1989-11-22 | 1990-10-23 | Becton, Dickinson And Company | Needle sheath assembly |
EP0525525B1 (en) | 1991-07-24 | 1995-05-03 | Medico Development Investment Company | Injector |
DE4229068C2 (en) | 1992-09-01 | 1994-06-16 | Bosch Gmbh Robert | Accelerator switch and manufacturing method |
EP0693946B1 (en) | 1993-03-24 | 2001-05-16 | Owen Mumford Limited | Improvements relating to injection devices |
US5478316A (en) | 1994-02-02 | 1995-12-26 | Becton, Dickinson And Company | Automatic self-injection device |
US5843036A (en) | 1996-08-23 | 1998-12-01 | Becton Dickinson And Company | Non-dosing cartridge for an injection device |
IE970782A1 (en) | 1997-10-22 | 1999-05-05 | Elan Corp | An improved automatic syringe |
AU4883797A (en) | 1997-11-03 | 1999-05-24 | Ermanno Greco | Self-injection device |
DK1003581T3 (en) | 1998-01-30 | 2000-12-18 | Novo Nordisk As | Syringe |
GB9808408D0 (en) | 1998-04-18 | 1998-06-17 | Owen Mumford Ltd | Improvements relating to injection devices |
DE19819409A1 (en) | 1998-04-30 | 1999-11-11 | Schering Ag | Injection device |
DE19822031C2 (en) | 1998-05-15 | 2000-03-23 | Disetronic Licensing Ag | Auto injection device |
SE9803662D0 (en) | 1998-10-26 | 1998-10-26 | Pharmacia & Upjohn Ab | autoinjector |
JP4838468B2 (en) | 1999-07-30 | 2011-12-14 | メドラッド インコーポレーテッド | Injector system and syringe adapter used in the injector system |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
FR2799375B1 (en) | 1999-10-07 | 2002-01-18 | Marc Brunel | SINGLE USE INJECTION DEVICE |
US6673035B1 (en) | 1999-10-22 | 2004-01-06 | Antares Pharma, Inc. | Medical injector and medicament loading system for use therewith |
US6692472B2 (en) | 2000-05-04 | 2004-02-17 | Novo Nordisk A/S | Injection device, a preassembled dose setting and injection mechanism for an injection device, and a method of assembling an injection device |
US6663602B2 (en) | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
WO2002017996A1 (en) | 2000-08-29 | 2002-03-07 | Novo Nordisk A/S | Automatic injection device with torsion function for retraction of needle |
SE518981C2 (en) | 2000-12-14 | 2002-12-17 | Shl Medical Ab | autoinjector |
PT1392377E (en) | 2001-05-16 | 2007-05-31 | Lilly Co Eli | Medication injector apparatus with drive assembly that facilitates reset |
US20030105430A1 (en) | 2001-11-30 | 2003-06-05 | Elan Pharma International Limited Wil House | Automatic injector |
EP1472477B1 (en) | 2002-01-25 | 2005-11-16 | Novo Nordisk A/S | Linear actuator and a medical delivery device comprising such linear actuator |
DE10237258B4 (en) | 2002-08-14 | 2006-09-21 | Tecpharma Licensing Ag | injection device |
GB0229345D0 (en) | 2002-12-17 | 2003-01-22 | Safe T Ltd | Hollow needle applicators |
US6846302B2 (en) * | 2002-12-31 | 2005-01-25 | Teva Medical Ltd. | Needle protector device |
GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
US20050027255A1 (en) | 2003-07-31 | 2005-02-03 | Sid Technologies, Llc | Automatic injector |
DE20311996U1 (en) | 2003-08-01 | 2003-10-16 | Hoelzle Dieter Tech Projekte | injection device |
JP4718462B2 (en) | 2003-08-12 | 2011-07-06 | イーライ リリー アンド カンパニー | Three-threaded drug delivery device for mechanical advantage |
DE10342058B4 (en) | 2003-09-11 | 2007-10-25 | Tecpharma Licensing Ag | Administration device for an injectable product with a trigger safety device |
IL157981A (en) | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto-injector |
DE10351596B4 (en) | 2003-11-05 | 2007-10-11 | Tecpharma Licensing Ag | Autoinjector with variable dose |
US20050101919A1 (en) | 2003-11-07 | 2005-05-12 | Lennart Brunnberg | Device for an injector |
EP1541185A1 (en) | 2003-12-08 | 2005-06-15 | Novo Nordisk A/S | Automatic syringe with priming mechanism |
WO2005058396A1 (en) | 2003-12-18 | 2005-06-30 | Tecpharma Licensing Ag | Releasable injection device |
US20050222539A1 (en) | 2004-03-30 | 2005-10-06 | Pediamed Pharmaceuticals, Inc. | Automatic injection device |
GB2414775B (en) | 2004-05-28 | 2008-05-21 | Cilag Ag Int | Releasable coupling and injection device |
GB2414401B (en) | 2004-05-28 | 2009-06-17 | Cilag Ag Int | Injection device |
JP4990151B2 (en) | 2004-10-21 | 2012-08-01 | ノボ・ノルデイスク・エー/エス | Syringe with internal dose indicator |
DK1819382T3 (en) | 2004-10-21 | 2010-02-15 | Novo Nordisk As | Injection device with torsion spring and swivel display |
JP4934051B2 (en) | 2004-11-24 | 2012-05-16 | エスホーエル メディカル アクチボラゲット | Injection device |
AU2005310060B2 (en) | 2004-11-24 | 2010-01-14 | Shl Medical Ag | Injection device |
DE102004063647A1 (en) | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Device for metered administration of a fluid product with coupling |
CA2595069C (en) | 2005-01-18 | 2011-05-03 | Wockhardt Americas Inc | Pen shaped medication injection devices |
AU2006207744B2 (en) | 2005-01-21 | 2011-08-11 | Novo Nordisk A/S | An automatic injection device with a top release mechanism |
GB2424838B (en) | 2005-04-06 | 2011-02-23 | Cilag Ag Int | Injection device (adaptable drive) |
DE102005063497B4 (en) | 2005-05-24 | 2009-09-24 | Tecpharma Licensing Ag | Plastic spring |
ES2314568T3 (en) | 2005-06-01 | 2009-03-16 | Shl Group Ab | DEVICE FOR THE DELIVERY OF MEDICINAL PRODUCT. |
US9011386B2 (en) | 2005-06-01 | 2015-04-21 | Shl Group Ab | Device for delivering medicament |
DE102005025424A1 (en) | 2005-06-02 | 2006-12-07 | Tecpharma Licensing Ag | Injection device, especially automatic injector or injection pen, has drive-off member propelled by surrounding torsional spring, for efficient delivery of product to patient |
WO2007006662A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Injection device |
DE102005052502A1 (en) | 2005-11-03 | 2007-05-16 | Tecpharma Licensing Ag | Auto-injector activation trigger element |
GB2433032A (en) | 2005-12-08 | 2007-06-13 | Owen Mumford Ltd | Syringe with dose adjustment means |
GB0601309D0 (en) | 2006-01-23 | 2006-03-01 | Medical House The Plc | Injection device |
US20090005735A1 (en) | 2006-03-03 | 2009-01-01 | Shl Group Ab | Medical Device with Orientation Sensitive Priming Mechanism |
FR2899482A1 (en) | 2006-04-11 | 2007-10-12 | Becton Dickinson France Soc Pa | Automatic medicament/product injection device for patient, has safety shield coupled to housing, and provided in active state at end of needle insertion step before which product/medicament injection step is not started |
WO2007129324A2 (en) | 2006-05-09 | 2007-11-15 | Gil Yigal | A disposable injecting device with auto-retraction mechanism |
GB2438591B (en) | 2006-06-01 | 2011-07-13 | Cilag Gmbh Int | Injection device |
GB2438592B (en) | 2006-06-01 | 2011-04-06 | Cilag Gmbh Int | Injection device |
GB2438629B (en) | 2006-06-01 | 2011-02-23 | Cilag Gmbh Int | Injection device |
TWI527603B (en) * | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | Automatic injection device |
DE102006038103B4 (en) | 2006-08-14 | 2017-02-23 | Tecpharma Licensing Ag | Injection device with variable thread guide |
JP2010503430A (en) | 2006-09-15 | 2010-02-04 | テクファーマ・ライセンシング・アクチェンゲゼルシャフト | Injection device with low loss drive |
FR2908753B1 (en) | 2006-11-16 | 2011-11-11 | Becton Dickinson France | DEVICE FOR AUTOMATICALLY DELIVERING SUCCESSIVE PRODUCT DOSES |
ATE514443T1 (en) | 2006-12-13 | 2011-07-15 | Shl Group Ab | AUTOINJECTOR |
DE202007000578U1 (en) | 2007-01-15 | 2007-03-08 | Cilag Gmbh International | Injection device for operating with a nozzle has a cap with corresponding threads, a casing, an outlet opening, a sleeve and a central hub |
CA2680335C (en) | 2007-03-09 | 2014-01-14 | Eli Lilly And Company | Delay mechanism for automatic injection device |
WO2008116688A1 (en) | 2007-03-23 | 2008-10-02 | Shl Medical Ab | Auto injector |
DK2144649T3 (en) | 2007-04-05 | 2011-10-31 | Tecpharma Licensing Ag | Management device with functional drive means |
DE102007016811A1 (en) | 2007-04-05 | 2008-10-09 | Tecpharma Licensing Ag | Device for administering a fluid substance from a multi-chamber ampoule |
CA2702412C (en) | 2007-06-19 | 2012-07-17 | Shl Group Ab | Device for delivering medicament |
US9242044B2 (en) | 2007-07-06 | 2016-01-26 | Novo Nordisk A/S | Automatic injection device |
ATE501749T1 (en) | 2007-07-06 | 2011-04-15 | Shl Group Ab | MONOINJECTOR WITH DOUBLE SPRINGS |
US8038649B2 (en) | 2007-09-18 | 2011-10-18 | Shl Group Ab | Automatic injection device with needle insertion |
WO2009040602A1 (en) | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
EP2211945B1 (en) | 2007-09-25 | 2017-09-20 | Becton Dickinson France | Autoinjector received in external socket |
CN101854967B (en) | 2007-09-25 | 2013-06-05 | 贝克顿迪金森法国公司 | Autoinjector with deactivating means moveable by a safety shield |
US8876779B2 (en) | 2007-11-12 | 2014-11-04 | Bang & Olufsen Medicom A/S | Auto injector with changing anchor locations for a mechanical driver |
US8992484B2 (en) | 2008-01-23 | 2015-03-31 | Novo Nordisk A/S | Device for injecting apportioned doses of liquid drug |
DE102008006300A1 (en) | 2008-01-28 | 2009-08-06 | Tecpharma Licensing Ag | Plastic spring |
EP2254624B1 (en) | 2008-02-12 | 2014-07-02 | SHL Group AB | Auto-injector |
DE102008011885A1 (en) | 2008-02-29 | 2009-09-10 | Tecpharma Licensing Ag | Dual function spring |
US8177749B2 (en) | 2008-05-20 | 2012-05-15 | Avant Medical Corp. | Cassette for a hidden injection needle |
EP2123317A1 (en) | 2008-05-20 | 2009-11-25 | Sanofi-Aventis Deutschland GmbH | Drive assembly suitable for use in drug delivery device and drug delivery device |
AU2009279719B2 (en) | 2008-08-05 | 2015-07-23 | Antares Pharma, Inc. | Multiple dosage injector |
KR20110052685A (en) | 2008-08-05 | 2011-05-18 | 칠드런'즈 메디컬 센터 코포레이션 | Medical devices for use in the surgical treatment of hyperproliferative diseases affecting the spinal cord |
DE102008037310B4 (en) | 2008-08-11 | 2023-11-16 | Ypsomed Ag | Automatic injection device for administering a fixed dose |
US8323238B2 (en) | 2008-09-18 | 2012-12-04 | Becton, Dickinson And Company | Medical injector with rotatable body portions |
CN102186521B (en) | 2008-09-18 | 2013-07-24 | 贝克顿·迪金森公司 | Medical injector with dose knob activation for automated reconstitution |
EP2362794B1 (en) | 2008-09-29 | 2019-04-03 | Becton Dickinson France | Automatic injection device with audible indicator of completed injection |
WO2010035060A1 (en) | 2008-09-29 | 2010-04-01 | Becton Dickinson France | Automatic injection device |
ES2447845T3 (en) | 2008-10-01 | 2014-03-13 | Shl Group Ab | Conical spiral spring-driven medication delivery device |
DK2346552T4 (en) * | 2008-10-13 | 2020-03-23 | Sanofi Aventis Deutschland | PHARMACEUTICAL PARTICULARS |
TWI555546B (en) | 2008-12-02 | 2016-11-01 | 賽諾菲阿凡提斯德意志有限公司 | Medication delivery device and method for operating a medication delivery device |
CA2746016A1 (en) | 2008-12-12 | 2010-06-17 | Sanofi-Aventis Deutschland Gmbh | Resettable drive mechanism for a medication delivery device and medication delivery device |
US9089652B2 (en) | 2008-12-12 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a medication delivery device and medication delivery device |
US8968258B2 (en) | 2008-12-12 | 2015-03-03 | Sanofi-Aventis Deutschland Gmbh | Resettable drive mechanism for a medication delivery device and medication delivery device |
EP2196233A1 (en) | 2008-12-12 | 2010-06-16 | Sanofi-Aventis Deutschland GmbH | Resettable drive mechanism for a medication delivery device and medication delivery device |
US8840591B2 (en) | 2008-12-12 | 2014-09-23 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a medication delivery device and medication delivery device |
GB0900930D0 (en) | 2009-01-20 | 2009-03-04 | Future Injection Technologies Ltd | Injection device |
EP2208503A1 (en) | 2009-01-20 | 2010-07-21 | Sanofi-Aventis Deutschland GmbH | Drive assembly and medication delivery device |
KR20110113203A (en) | 2009-02-05 | 2011-10-14 | 사노피-아벤티스 도이칠란트 게엠베하 | Medicament delivery devices |
AR075234A1 (en) | 2009-02-05 | 2011-03-16 | Sanofi Aventis Deutschland | DRUG ADMINISTRATION DEVICES. |
WO2010097116A1 (en) | 2009-02-26 | 2010-09-02 | Tecpharma Licensing Ag | Product container holder for an injection device and for receiving a product container |
CN102348476B (en) | 2009-03-13 | 2014-06-25 | 伊莱利利公司 | Apparatus for injecting a pharmaceutical with automatic syringe retraction following injection |
AU2010226442A1 (en) | 2009-03-20 | 2011-10-13 | Antares Pharma, Inc. | Hazardous agent injection system |
DK2414004T3 (en) | 2009-03-31 | 2015-07-27 | Sanofi Aventis Deutschland | Improvements in and relating to devices for drug feed |
ES2633664T5 (en) | 2009-05-26 | 2023-07-11 | Shl Medical Ag | needle cover assembly |
DK2954914T3 (en) | 2009-05-29 | 2019-03-11 | Tecpharma Licensing Ag | Injection device, especially auto-injector with plug protection and / or overload protection for a product container |
WO2010136077A1 (en) | 2009-05-29 | 2010-12-02 | Tecpharma Licensing Ag | Injection device, especially auto-injector comprising a switching device for a needle protection sleeve |
US9457150B2 (en) | 2009-06-01 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Biasing mechanism for a drug delivery device |
WO2010140974A1 (en) | 2009-06-05 | 2010-12-09 | Shl Group Ab | Medicament delivery device |
TWI393578B (en) | 2009-07-07 | 2013-04-21 | Shl Group Ab | Injection device |
GB0913385D0 (en) | 2009-07-31 | 2009-09-16 | Medical House The Plc | Improved autoinjector |
AR078457A1 (en) | 2009-09-30 | 2011-11-09 | Sanofi Aventis Deutschland | DRIVING MECHANISM FOR A DRUG DISCHARGE DEVICE |
EP3023114A1 (en) | 2009-10-08 | 2016-05-25 | SHL Group AB | Medicament delivery device |
US9233213B2 (en) | 2009-10-16 | 2016-01-12 | Janssen Biotech, Inc. | Palm activated drug delivery device |
GB0918145D0 (en) | 2009-10-16 | 2009-12-02 | Owen Mumford Ltd | Injector apparatus |
ES2680668T3 (en) | 2009-10-16 | 2018-09-10 | Janssen Biotech, Inc. | Drug delivery device activated with the palm of the hand |
WO2011053225A1 (en) | 2009-10-26 | 2011-05-05 | Shl Group Ab | Medicament delivery device |
DK2536451T3 (en) | 2010-02-18 | 2018-07-16 | Sanofi Aventis Deutschland | Auto injector with a torsion spring |
DK2536453T3 (en) | 2010-02-18 | 2014-11-24 | Sanofi Aventis Deutschland | autoinjector |
EP2536455B1 (en) | 2010-02-18 | 2014-03-26 | Sanofi-Aventis Deutschland GmbH | Finger guard for an injection device |
JP5855022B2 (en) * | 2010-02-22 | 2016-02-09 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Power transmission arrangement for automatic syringes |
DK2538996T3 (en) | 2010-02-22 | 2020-08-10 | Sanofi Aventis Deutschland | AUTO INJECTOR WITH NEEDLE CASES AND NEEDLE PROTECTION CAP |
DK2538993T3 (en) | 2010-02-22 | 2017-02-06 | Sanofi Aventis Deutschland | Auto injector with gearbox |
DK2542280T3 (en) | 2010-03-01 | 2014-10-20 | Lilly Co Eli | AUTOMATIC INJECTION DEVICE WITH DELAY MECHANISM INCLUDING DOUBLE FUNCTIONING PRESENT |
EP2364740A1 (en) | 2010-03-09 | 2011-09-14 | Sanofi-Aventis Deutschland GmbH | Arrangement for transferring a translation of a drive means to a plunger |
EP2544741B1 (en) | 2010-03-09 | 2016-05-11 | SHL Group AB | Medicament delivery device |
IT1398501B1 (en) | 2010-03-10 | 2013-03-01 | Menarini Int Operations Lu Sa | AUTOINECTOR DEVICE FOR TWO DRUG DOSES |
ES2896727T3 (en) | 2010-03-25 | 2022-02-25 | New Injection Systems Ltd | Injector |
CN103120820B (en) | 2010-03-31 | 2015-03-11 | Shl集团有限责任公司 | Medicament delivery device |
WO2011126439A1 (en) | 2010-04-07 | 2011-10-13 | Shl Group Ab | Medicament delivery device |
WO2011136718A1 (en) | 2010-04-26 | 2011-11-03 | Shl Group Ab | Medicament delivery device |
JP5512883B2 (en) | 2010-05-07 | 2014-06-04 | エス・ホー・エル・グループ・アクチボラゲット | Drug delivery device |
JP5873485B2 (en) | 2010-06-11 | 2016-03-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Drive mechanism for drug delivery device and drug delivery device |
CA2801158A1 (en) | 2010-06-11 | 2011-12-15 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a drug delivery device and drug delivery device |
US8961473B2 (en) | 2010-06-11 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a drug delivery device and drug delivery device |
CA2803154A1 (en) | 2010-06-28 | 2012-01-05 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
EP2399631A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector with injection damper |
EP2399633A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Needle safety arrangement and method for operating it |
EP2399635A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2399634A1 (en) | 2010-06-28 | 2011-12-28 | Sanofi-Aventis Deutschland GmbH | Needle safety arrangement and method for operating it |
DK2555820T3 (en) | 2010-07-02 | 2015-03-23 | Carebay Holding Ltd Company No 681498 | Dispensing device for follicle stimulating hormone solution without preservatives |
EP2588162B1 (en) | 2010-07-02 | 2020-01-01 | Sanofi-Aventis Deutschland GmbH | Safety device for a pre-filled syringe and injection device |
RU2459639C2 (en) | 2010-09-29 | 2012-08-27 | Александр Ильич Абовян | Disposable cartridge injector |
EP2624882B1 (en) | 2010-10-06 | 2021-04-28 | Ypsomed AG | Locking and retaining mechanism for the needle guard sleeve of an injection device |
EP2438942A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2438944A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2452711A1 (en) | 2010-11-12 | 2012-05-16 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for a drug delivery device and drug delivery device |
TWI476024B (en) | 2010-11-18 | 2015-03-11 | Shl Group Ab | Medicament delivery device |
US9220846B2 (en) | 2010-11-26 | 2015-12-29 | Sanofi-Aventis Deutschland Gmbh | Medicated module for an ophthalmic drug delivery device |
EP2468338A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468336A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468335A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468329A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto injector with a torsion spring |
EP2468334A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468332A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468330A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
USRE48593E1 (en) | 2010-12-21 | 2021-06-15 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
EP2468333A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468331A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2468337A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Back-end device for an auto-injector and auto-injector |
EP2468342A1 (en) | 2010-12-21 | 2012-06-27 | Sanofi-Aventis Deutschland GmbH | Front end for an auto-injector |
EP2489382A1 (en) | 2011-02-18 | 2012-08-22 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
EP2540329A1 (en) | 2011-06-28 | 2013-01-02 | Sanofi-Aventis Deutschland GmbH | Needle assembly attachment and removal device |
CH705345A2 (en) | 2011-08-04 | 2013-02-15 | Tecpharma Licensing Ag | Injector with needle protection device. |
EP2601992A1 (en) | 2011-12-08 | 2013-06-12 | Sanofi-Aventis Deutschland GmbH | Syringe carrier |
KR101924310B1 (en) | 2011-12-15 | 2018-11-30 | 에스에이치엘 그룹 에이비 | Auto-injection device |
EP2656865A1 (en) | 2012-04-24 | 2013-10-30 | Sanofi-Aventis Deutschland GmbH | Syringe carrier with needle shield and data storage device for use in a medical auto-injection device |
CH705992A2 (en) | 2012-10-11 | 2013-06-14 | Tecpharma Licensing Ag | Injection device for injecting e.g. liquid medication to tissue, has trigger unit that is movable in relation to housing to cause holding sleeve to release drive unit such that drive unit is triggered by distal movement of trigger unit |
EP2722066A1 (en) | 2012-10-16 | 2014-04-23 | Sanofi-Aventis Deutschland GmbH | Medicament container carrier |
EP2781230B1 (en) | 2013-03-22 | 2019-08-21 | TecPharma Licensing AG | Substance dispensing device with a signaling device |
EP2823841A1 (en) * | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
EP2823840A1 (en) | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
GB201313888D0 (en) | 2013-08-02 | 2013-09-18 | Consort Medical Plc | Assembly for an autoinjector device |
CH707898A2 (en) | 2014-07-29 | 2014-10-15 | Tecpharma Licensing Ag | Autoinjector with adjustable dose. |
CN112870489B (en) | 2015-04-24 | 2022-12-06 | 艾斯曲尔医疗公司 | Sub-assembly of a medicament delivery device and medicament delivery device |
TW201707738A (en) | 2015-06-03 | 2017-03-01 | 賽諾菲阿凡提斯德意志有限公司 | Syringe support and autoinjector |
CH711240A2 (en) | 2015-06-23 | 2016-12-30 | Tecpharma Licensing Ag | Auto injection device. |
WO2017071909A1 (en) | 2015-10-28 | 2017-05-04 | Carebay Europe Ltd | Medicament container holder |
KR102651644B1 (en) | 2019-07-18 | 2024-03-27 | 에스에이치엘 메디컬 아게 | Support structures, drug delivery devices, and assembly methods |
WO2021160540A1 (en) | 2020-02-11 | 2021-08-19 | Ypsomed Ag | Auto-injector comprising a needle protection sleeve |
CH717267A2 (en) | 2020-03-30 | 2021-09-30 | Ypsomed Ag | Auto-injector with a multi-chamber product container. |
CH717905A2 (en) | 2020-09-30 | 2022-03-31 | Ypsomed Ag | Auto-injector with pouring stop. |
CH717046A2 (en) | 2021-03-04 | 2021-07-15 | Ypsomed Ag | Auto-injector with a needle protection sleeve. |
-
2016
- 2016-06-01 TW TW105117156A patent/TW201707738A/en unknown
- 2016-06-02 US US15/579,146 patent/US11266782B2/en active Active
- 2016-06-02 AU AU2016269707A patent/AU2016269707B2/en active Active
- 2016-06-02 EP EP16726333.4A patent/EP3302635A1/en active Pending
- 2016-06-02 AR ARP160101627A patent/AR104873A1/en unknown
- 2016-06-02 WO PCT/EP2016/062461 patent/WO2016193355A1/en active Application Filing
- 2016-06-02 MX MX2017015511A patent/MX2017015511A/en unknown
- 2016-06-02 JP JP2017562766A patent/JP6856549B2/en active Active
- 2016-06-02 CN CN202310890302.XA patent/CN117085210A/en active Pending
- 2016-06-02 KR KR1020177037819A patent/KR102614624B1/en active IP Right Grant
- 2016-06-02 CN CN201680032311.3A patent/CN107683154B/en active Active
- 2016-06-02 BR BR112017025749-1A patent/BR112017025749B1/en active IP Right Grant
- 2016-06-02 RU RU2017146127A patent/RU2720168C2/en active
- 2016-06-02 KR KR1020237042961A patent/KR20230175320A/en not_active Application Discontinuation
-
2017
- 2017-11-30 IL IL256011A patent/IL256011A/en unknown
-
2018
- 2018-06-22 HK HK18107997.8A patent/HK1249456A1/en unknown
-
2022
- 2022-02-08 US US17/666,696 patent/US11400216B2/en active Active
- 2022-05-06 US US17/738,644 patent/US20220370717A1/en active Pending
-
2023
- 2023-02-06 US US18/106,278 patent/US11752266B2/en active Active
-
2024
- 2024-01-16 US US18/413,701 patent/US12042636B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12042636B2 (en) | 2015-06-03 | 2024-07-23 | Sanofi-Aventis Deutschland Gmbh | Syringe support and autoinjector |
Also Published As
Publication number | Publication date |
---|---|
HK1249456A1 (en) | 2018-11-02 |
US11266782B2 (en) | 2022-03-08 |
AR104873A1 (en) | 2017-08-23 |
CN107683154A (en) | 2018-02-09 |
US12042636B2 (en) | 2024-07-23 |
US20230181828A1 (en) | 2023-06-15 |
EP3302635A1 (en) | 2018-04-11 |
RU2017146127A3 (en) | 2019-11-25 |
IL256011A (en) | 2018-01-31 |
RU2017146127A (en) | 2019-07-09 |
BR112017025749B1 (en) | 2023-03-28 |
TW201707738A (en) | 2017-03-01 |
CN107683154B (en) | 2023-08-04 |
US20220152305A1 (en) | 2022-05-19 |
KR20230175320A (en) | 2023-12-29 |
RU2720168C2 (en) | 2020-04-24 |
BR112017025749A2 (en) | 2018-08-14 |
JP6856549B2 (en) | 2021-04-07 |
JP2018516688A (en) | 2018-06-28 |
MX2017015511A (en) | 2018-02-21 |
US20240148974A1 (en) | 2024-05-09 |
WO2016193355A1 (en) | 2016-12-08 |
KR20180015679A (en) | 2018-02-13 |
AU2016269707A1 (en) | 2018-01-18 |
KR102614624B1 (en) | 2023-12-18 |
US20180161504A1 (en) | 2018-06-14 |
AU2016269707B2 (en) | 2020-12-10 |
CN117085210A (en) | 2023-11-21 |
US11752266B2 (en) | 2023-09-12 |
US11400216B2 (en) | 2022-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11400216B2 (en) | Syringe support and autoinjector | |
US20210338940A1 (en) | Grasper for a needle sheath, cap, autoinjector and method of producing a grasper | |
US20210322683A1 (en) | Shroud lock | |
US20210077743A1 (en) | Syringe Carrier for an Autoinjector and Method of Assembling | |
US20210252223A1 (en) | Syringe Support and Autoinjector | |
US11759578B2 (en) | Needle shroud assembly and drug delivery device | |
US11771838B2 (en) | Audible indicator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEMP, THOMAS MARK;HODGSON, LOUISE;REEL/FRAME:059866/0858 Effective date: 20160715 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |